Compare Cintas Corporation (CTAS) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Enveric Biosciences Inc — how do they compare? Cintas Corporation trades at $200.75 (market cap $78.78B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Cintas Corporation is far larger — about 11775.8× Enveric Biosciences Inc's market cap, and Cintas Corporation pays a 1.05% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Enveric Biosciences Inc for 14 Days on average.
| CTAS | ENVB | |
|---|---|---|
Market Cap | $78.78B | $6.69M |
Volume | 1,620,783 | 41,141 |
Sector | Industrials | Health |
52-Week High | $216.53 | $10.80 |
52-Week Low | $163.55 | $1.27 |
Typical Hold Time | 124 Days | 14 Days |
Enterprise Value | $81.25B | -$1.60M |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal and strong fundamental performance. Recent Q1 2027 earnings beat expectations with revenue of $3.01 billion and EPS of $1.39, driven by organic growth and margin expansion. The company raised fiscal 2027 guidance, reflecting confidence in continued momentum. Valuation multiples remain elevated with a P/E of 38.89, supported by robust profitability metrics including a 17.82% net income margin and 42.08% ROE.
The outlook for CTAS is positive, with earnings growth and raised guidance serving as key catalysts for potential upside toward the consensus price target of $234.60. Risks include high valuation sensitivity to growth sustainability and competitive pressures in the uniform rental sector. Analyst sentiment is moderately bullish, with 40% buy ratings, but investors should monitor execution against elevated expectations.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
